Author Archives: Bernard Smyth

Retired journalist, ex Fleet Street and managing editor at Home Office, London

Hormone treatment and Covid-19

Hormone treatment might offer some protection from Covid-19, it’s reported. See more here And it can make PCa worse, this study finds.  An online survey aiming to shed more light on the experience of PCa patients on this therapy (aged 35 to 80) is being conducted via this link And a London college has developed […]

Chemo swapped for precision drugs

Advanced PCa patients can take enzalutamide or abiraterone at home instead of going into hospital for chemotherapy, NHS England says. It will relieve pressure on the NHS. The drugs are smarter, kinder treatments and could extend the lives of many more men, it’s said (May ’20). See more here: And a new treatment is being […]

Tracking down tumours

A radical ‘seek and destroy’ treatment could extend the lives of thousands of men with advanced PCa. The approach is described by experts as ‘game changing’ (Jun ’19). See more at

Cancer can be detected much earlier

  The first signs of cancer can appear decades before diagnosis, scientists have found – a discovery that could revolutionise treatment (Feb ’20). See more here. And Public Health England has published a statistical bulletin on survival rates for many types of cancer based on recent data. It stressses the importance of early diagnosis. A […]

Next meeting

  Meetings changed and ‘coffee mornings’ These meetings have had to be changed so we can have a guest speaker: The March 8 one is moved to March 22. It will be a Zoom members’ meeting and a talk by Prof Mark Emberton (UCLH), a leading light on the PROMIS trial. Wed April 21 – […]

Patient guide ‘good source of info’

Prostate Cancer Foundation’s 2019 Patient Guide is said to be one of the best sources of information from diagnosis to survival of PCa. Download it for free here.  Our New Research page is updated regularly.

Drugs approved and a PCa ‘killer’

The NHS confirmed that the chemotherapy drug docetaxel will be made available to prostate cancer patients as soon as they are diagnosed instead of having to wait until other treatments stop working. See. And NICE has approved a new drug, Darolutamide, as an option for treating hormone-relapsed PCa in men at high risk of developing […]